Table 4.
Laboratory and Weight Measures
| Valproic Acid | Risperidone | Placebo | ||||||
|---|---|---|---|---|---|---|---|---|
| Baseline | End-point | Baseline | End-point | Baseline | End-point | Between-group F value | Normal values for age | |
| Bilirubin unconjugated mg/dL | 0.40±0.3 | 0.37±0.2a | 0.33±0.19 | 0.37±0.2a | 0.27±0.2 | 0.29±0.2a | F(2,44)=0.38, p=0.68 | <1 |
| Serum glutamic oxaloacetic transaminase(SGOT) units/L | 50.8±16 | 51.8±14.2 | 49±10 | 58.5±15.3 | 54.7±9.7 | 51.5±12 | F(2,44)=1.0, p=0.38 | 15–46 |
| Alanine aminotransferase (ALT/SGPT) units/L | 22.5±13 | 16.9±7.3 | 20.3±9 | 23.4±9.2 | 31.7±12 | 22.2±6 | F(2,44)=0.2.65, p=0.08 | 8–36 |
| γ-glutamyl transferase (GGT) U/L | 16.9+5 | 16.2+3 | 14.7+2.5 | 17.8+2.5a | 17.2+2 | 16.8+1.2 | F(2,44)=1.61, p=0.22 | 7–19 |
| Albumin g/dL | 4.5±0.2 | 4.1±0.2a | 4.5±0.3 | 4.5±0.2 | 4.5±0.1 | 4.5±0.2 | F(2,44)=12.46, p=0.001 | 3.5–5.5 |
| Total cholesterol mg/dL | 161±20 | 164.8±33a | 162.3±22 | 170.1±19a | 149.5±14 | 167±13a | F(2,44)=0.16, p=0.85 | 135–200 |
| Triglycerides mg/dL | 79.6±34 | 86.2±43 | 78.2±46 | 99.5±90 | 81.1±37 | 108.6±75 | F(2,44)=0.24, p=0.79 | <45 |
| Low density lipoproteins mg/dL | 92.3±22 | 93.83±31 | 95±17 | 98±19 | 87.2±15 | 97.3±13 | F(2,44)=0.15, p=0.89 | <190 |
| High density lipoproteins mg/dL | 53.6±11 | 53.7±13 | 51±9 | 55±7 | 46±10 | 48±9 | F(2,44)=0.1.14, p=0.33 | <110 |
| Red blood cell count mill/mm3 | 4.7±0.4 | 4.5±0.3a | 4.6±0.3 | 4.5±0.3 | 4.5±0.2 | 4.5±0.2 | F(2,44)=0.13, p=0.88 | 4.0–4.9 |
| Hemoglobin g/dL | 13.1±0.6 | 12.61±0.59a | 12.5±0.7 | 12.5±0.9 | 13±0.9 | 12.8±0.8 | F(2,44)=0.31, p=0.74 | 11.5–14.5 |
| Hematocrit % | 38.50±2.36 | 36.73±1.54a | 37.08±2.5 | 36.6±2.5 | 37.4±2.6 | 37.8±2.3 | F(2,44)=0.87, p=0.43 | 35–42 |
| Platelets×103/mm3 | 357+80 | 319+92 | 374.8+77 | 362.2+53 | 342+55 | 366+46 | F(2,44)=1.7, p=0.20 | 250–550 |
| Prolactin level ng/mL | 7.43±4.5 | 5.25±1.3 | 8.7±4.2 | 53.9±20a | 5.1±1.7 | 6.9±2.5 | F(2,44)=56, p=0.001 | 1.2–12.95 |
| Insulin level mU/L | 14.87±10 | 17.8±10 | 10±1.0 | 14±1.0 | 17.2±3.2 | 7.3±3.5a | F(2,44)=1.66, p=0.22 | 1.8–24.6 |
| Weight (kg) | 25.3±6.4 | 25.8±7.2a | 20.7±5.2 | 21.4±5.4a | 20.7±4.5 | 20.8±4.5 | F(2,44)=2.65, p=0.09 | |
| Body mass index | 17.4±2.2 | 19.0±3.4a | 16.8±3.0 | 17.0±2.1 | 16.2±0.9 | 16.3±1.0 | F(2,44)=03.39, p=0.04 | |
a
p<0.05 versus baseline within the valproate, risperidone, or placebo-treated groups.